{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:51:12Z","timestamp":1775587872947,"version":"3.50.1"},"reference-count":31,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2020,11,13]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>High-grade serous ovarian carcinoma (HGSOC) is one of the most common\novarian epithelial carcinomas. It is highly invasive, easily recurs after systemic treatment, and has a poor\nprognosis. Despite many new chemotherapeutic drugs and trials of combinations of different regimens\nthat have been used in treatment attempts, there has been no meaningful progress in the treatment of\nHGSOC. With the development of gene sequencing technology, gene therapy has become a new direction\nfor tumors treatment. It is reported that the P53 has a very high mutation rate in HGSOC, which provides\na theoretical basis for the application of gene therapy in HGSOC patients. Recombinant human p53\nadenovirus injection (rAd-p53) is the world's first approved oncology gene therapy drug.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Report:<\/jats:title>\n<jats:p>In this article, we retrospectively analyzed 4 cases of HGSOC patients treated with rAdp53.\nThree of them were recurrent ovarian cancer, and one was the initial treatment. The treatment\nmethod was to apply recombinant human p53 adenovirus injection (rAd-p53) to the lesions for local\ninjection, 72 hours later, the lesions were injected with bleomycin or fluorouracil, and systemic intravenous\nchemotherapy was performed simultaneously. After rAd-p53 treatment, one of the three relapsed\novarian cancers achieved complete remission(CR), one achieved partial remission (PR), and\none was stable disease (SD); the treatment-naive patient was operated after rAd-p53 combined with\nneoadjuvant chemotherapy and achieved pathological CR. Under the action of various mechanisms of\nP53, the subsequent tumor treatment showed the characteristics of slow tumor progression, no ascites,\nand local recurrence. As of the end of follow-up, the OS of 4 patients was 71-120 months.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Through the remarkable efficacy of these 4 cases, we can see that the application of rAdp53\ncombined with chemotherapy can effectively control tumor lesions, prolong the survival time of patients,\nimprove the quality of life of patients, which provide valuable experiences for rAd-p53 treatment\nin ovarian cancer, promote the further development and progress of gene therapy in this field.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566523220666200826100245","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T20:31:44Z","timestamp":1598473904000},"page":"313-320","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer"],"prefix":"10.2174","volume":"20","author":[{"given":"Hui","family":"Qu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, No. 36, Sanhao Street, Heping District, Shenyang, Liaoning 110004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, No. 36, Sanhao Street, Heping District, Shenyang, Liaoning 110004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, No. 36, Sanhao Street, Heping District, Shenyang, Liaoning 110004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","volume":"164","author":"Shih IeM.","year":"2004","unstructured":"Shih IeM.; Kurman R.J.; Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004,164(5),1511-1518","journal-title":"Am J Pathol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"Ferlay J.","year":"2015","unstructured":"Ferlay J.; Soerjomataram I.; Dikshit R.; Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015,136(5),E359-E386","journal-title":"Int J Cancer"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc2946","volume":"10","author":"Bowtell D.D.","year":"2010","unstructured":"Bowtell D.D.; The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010,10(11),803-808","journal-title":"Nat Rev Cancer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"Ahmed A.A.","year":"2010","unstructured":"Ahmed A.A.; Etemadmoghadam D.; Temple J.; Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010,221(1),49-56","journal-title":"J Pathol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","year":"2011","unstructured":"Integrated genomic analyses of ovarian carcinoma. Nature Cancer Genome Atlas Research Network2011,474(7353),609-615","journal-title":"Nature"},{"key":"ref=6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114491","volume":"9","author":"Hayano T.","year":"2014","unstructured":"Hayano T.; Yokota Y.; Hosomichi K.; Molecular characterization of an intact p53 pathway subtype in high-grade serous ovarian cancer. PLoS One 2014,9(12)","journal-title":"PLoS One"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1002\/cam4.2243","volume":"8","author":"Zhong F.","year":"2019","unstructured":"Zhong F.; Zhu T.; Pan X.; Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras\/Raf pathway with TP53. Cancer Med 2019,8(8),3928-3935","journal-title":"Cancer Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/CAD.0000000000000448","volume":"28","author":"Ma W.S.","year":"2017","unstructured":"Ma W.S.; Ma J.G.; Xing L.N.; Efficacy and safety of recombinant human adenovirus p53 combined with chemoradiotherapy in the treatment of recurrent nasopharyngeal carcinoma. Anticancer Drugs 2017,28(2),230-236","journal-title":"Anticancer Drugs"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1200\/JCO.2008.18.9670","volume":"27","author":"Pan J.J.","year":"2009","unstructured":"Pan J.J.; Zhang S.W.; Chen C.B.; Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 2009,27(5),799-804","journal-title":"J Clin Oncol"},{"key":"ref=10","first-page":"225","volume":"39","author":"Wang J.","year":"2014","unstructured":"Wang J.; Wang X.; Yang J.; Treatment of local advanced non-small cell lung cancer with recombinant human p53adenovirus combined with radiochemotherapy. J Guiyang Med Coll 2014,39,225-228","journal-title":"J Guiyang Med Coll"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/cgt.2011.15","volume":"18","author":"Ning X.","year":"2011","unstructured":"Ning X.; Sun Z.; Wang Y.; Docetaxel plus trans-tracheal injection of adenoviral-mediated p53 versus docetaxel alone in patients with previously treated non-small-cell lung cancer. Cancer Gene Ther 2011,18(6),444-449","journal-title":"Cancer Gene Ther"},{"key":"ref=12","first-page":"19","volume":"36","author":"Xu Z.","year":"2015","unstructured":"Xu Z.; Quan X.; Jiang J.; Clinical observations of intensity modulated radiation therapy combined with recombinant human p53 adenovirus injection on middle-late type giant piece of cervical carcinoma. Anhui Med J 2015,36,19-22","journal-title":"Anhui Med J"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0090-8258(03)00054-4","volume":"89","author":"Huh J.J.","year":"2003","unstructured":"Huh J.J.; Wolf J.K.; Fightmaster D.L.; Lotan R.; Follen M.; Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells. Gynecol Oncol 2003,89(2),243-250","journal-title":"Gynecol Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1089\/hum.2017.206","volume":"29","author":"Xia Y.","year":"2018","unstructured":"Xia Y.; Du Z.; Wang X.; Li X.; Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy. Hum Gene Ther 2018,29(2),242-250","journal-title":"Hum Gene Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1074\/jbc.M111.228981","volume":"286","author":"Cross B.","year":"2011","unstructured":"Cross B.; Chen L.; Cheng Q.; Li B.; Yuan Z.M.; Chen J.; Inhibition of p53 DNA binding function by the MDM2 protein acidic domain. J Biol Chem 2011,286(18),16018-16029","journal-title":"J Biol Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/0092-8674(92)90243-6","volume":"70","author":"Livingstone L.R.","year":"1992","unstructured":"Livingstone L.R.; White A.; Sprouse J.; Livanos E.; Jacks T.; Tlsty T.D.; Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992,70(6),923-935","journal-title":"Cell"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/0092-8674(92)90244-7","volume":"70","author":"Yin Y.","year":"1992","unstructured":"Yin Y.; Tainsky M.A.; Bischoff F.Z.; Strong L.C.; Wahl G.M.; Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992,70(6),937-948","journal-title":"Cell"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1158\/1541-7786.MCR-17-0089","volume":"15","author":"Pappas K.","year":"2017","unstructured":"Pappas K.; Xu J.; Zairis S.; p53 Maintains baseline expression of multiple tumor suppressor genes. Mol Cancer Res 2017,15(8),1051-1062","journal-title":"Mol Cancer Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.tips.2004.02.009","volume":"25","author":"Hofseth L.J.","year":"2004","unstructured":"Hofseth L.J.; Hussain S.P.; Harris C.C.; p53: 25 years after its discovery. Trends Pharmacol Sci 2004,25(4),177-181","journal-title":"Trends Pharmacol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082330","volume":"8","author":"Xi D.","year":"2013","unstructured":"Xi D.; Wang M.; Ye H.; Luo X.; Ning Q.; Combined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice. PLoS One 2013,8(11)","journal-title":"PLoS One"},{"key":"ref=21","first-page":"954","volume":"25","author":"Gai X.D.","year":"2006","unstructured":"Gai X.D.; Li G.L.; Huang J.Z.; Xue H.J.; Wang D.; Reversal of multidrug resistance of human hepatocellular carcinoma cells by wild-type p53 gene and related mechanisms. Chin J Cancer 2006,25(8),954-959","journal-title":"Chin J Cancer"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0928-0987(00)00114-7","volume":"11","author":"Krishna R.","year":"2000","unstructured":"Krishna R.; Mayer L.D.; Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000,11(4),265-283","journal-title":"Eur J Pharm Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/CAD.0b013e328345b4e7","volume":"22","author":"Qi X.","year":"2011","unstructured":"Qi X.; Chang Z.; Song J.; Gao G.; Shen Z.; Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin. Anticancer Drugs 2011,22(6),556-562","journal-title":"Anticancer Drugs"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/jbt.20334","volume":"24","author":"Lee Y.S.","year":"2010","unstructured":"Lee Y.S.; Yoon S.; Park M.S.; Kim J.H.; Lee J.H.; Song C.W.; Influence of p53 expression on sensitivity of cancer cells to bleomycin. J Biochem Mol Toxicol 2010,24(4),260-269","journal-title":"J Biochem Mol Toxicol"},{"key":"ref=25","first-page":"3557","volume":"30","author":"Guntur V.P.","year":"2010","unstructured":"Guntur V.P.; Waldrep J.C.; Guo J.J.; Selting K.; Dhand R.; Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res 2010,30(9),3557-3564","journal-title":"Anticancer Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3892\/mmr.2014.2784","volume":"11","author":"Liu Q.","year":"2015","unstructured":"Liu Q.; Sui R.; Li R.; Miao J.; Liu J.; Biological characteristics of Taxol resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53. Mol Med Rep 2015,11(2),1292-1297","journal-title":"Mol Med Rep"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"Kipps E.","year":"2013","unstructured":"Kipps E.; Tan D.S.; Kaye S.B.; Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 2013,13(4),273-282","journal-title":"Nat Rev Cancer"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1054\/bjoc.2001.1933","volume":"85","author":"Fujimoto J.","year":"2001","unstructured":"Fujimoto J.; Sakaguchi H.; Aoki I.; Khatun S.; Tamaya T.; Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br J Cancer 2001,85(3),313-316","journal-title":"Br J Cancer"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1007\/s002800051102","volume":"43","author":"Shibuya M.","year":"1999","unstructured":"Shibuya M.; Luo J.C.; Toyoda M.; Yamaguchi S.; Involvement of VEGF and its receptors in ascites tumor formation. Cancer Chemother Pharmacol 1999,43,S72-S77","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-016-0497-3","volume":"15","author":"Bekes I.","year":"2016","unstructured":"Bekes I.; Friedl T.W.P.; K\u00f6hler T.; Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer? Mol Cancer 2016,15(15),13","journal-title":"Mol Cancer"},{"key":"ref=31","first-page":"6952","volume":"61","author":"Pal S.","year":"2001","unstructured":"Pal S.; Datta K.; Mukhopadhyay D.; Central role of p53 on regulation of vascular permeability factor\/vascular endothelial growth factor (VPF\/VEGF) expression in mammary carcinoma. Cancer Res 2001,61(18),6952-6957","journal-title":"Cancer Res"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185325","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185325\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:25:33Z","timestamp":1621538733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185325\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523220666200826100245","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}